Deciphering the roles of glycogen synthase kinase 3 (GSK3) in the treatment of autism spectrum disorder and related syndromes.

Autism Spectrum Disorder / drug therapy Glycogen Synthase Kinase 3 / metabolism Humans Signal Transduction Synapses / pathology Synaptic Transmission Syndrome
Autism spectrum disorder Fragile X syndrome Glycogen synthase kinase 3 Rett syndrome

Journal

Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 25 12 2020
accepted: 12 02 2021
pubmed: 3 3 2021
medline: 19 5 2021
entrez: 2 3 2021
Statut: ppublish

Résumé

Autism spectrum disorder (ASD) is a complex and multifactorial neurodevelopmental disorder characterized by the presence of restricted interests and repetitive behaviors besides deficits in social communication. Syndromic ASD is a subset of ASD caused by underlying genetic disorders, most commonly Fragile X Syndrome (FXS) and Rett Syndrome (RTT). Various mutations and consequent malfunctions in core signaling pathways have been identified in ASD, including glycogen synthase kinase 3 (GSK3). A growing body of evidence suggests a key role of GSK3 dysregulation in the pathogenesis of ASD and its related disorders. Here, we provide a synopsis of the implication of GSK3 in ASD, FXS, and RTT as a promising therapeutic target for the treatment of ASD.

Identifiants

DOI: 10.1007/s11033-021-06237-9 PMID: 33650079
pubmed: 33650079
doi: 10.1007/s11033-021-06237-9
pii: 10.1007/s11033-021-06237-9
doi:

Substances chimiques

Glycogen Synthase Kinase 3 EC 2.7.11.26

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2669-2686

Références

Elsabbagh M, Divan G, Koh YJ, Kim YS, Kauchali S, Marcin C, Montiel-Nava C, Patel V, Paula CS, Wang C, Yasamy MT, Fombonne E (2012) Global prevalence of autism and other pervasive developmental disorders. Autism Res 5(3):160–179. https://doi.org/10.1002/aur.239
doi: 10.1002/aur.239 pubmed: 22495912 pmcid: 3763210
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric Association Publishing. https://doi.org/10.1176/appi.books.9780890425596
doi: 10.1176/appi.books.9780890425596
Persico AM, Napolioni V (2013) Autism genetics. Behav Brain Res 251:95–112. https://doi.org/10.1016/j.bbr.2013.06.012
doi: 10.1016/j.bbr.2013.06.012 pubmed: 23769996
Lai M-C, Lombardo MV, Baron-Cohen S (2014) Autism. Lancet 383(9920):896–910. https://doi.org/10.1016/s0140-6736(13)61539-1
doi: 10.1016/s0140-6736(13)61539-1 pubmed: 24074734
Hur E-M, Zhou F-Q (2010) GSK3 signalling in neural development. Nat Rev Neurosci 11(8):539–551. https://doi.org/10.1038/nrn2870
doi: 10.1038/nrn2870 pubmed: 20648061 pmcid: 3533361
Lopez-Tobon A, Villa CE, Cheroni C, Trattaro S, Caporale N, Conforti P, Iennaco R, Lachgar M, Rigoli MT, Marco de la Cruz B, Lo Riso P, Tenderini E, Troglio F, De Simone M, Liste-Noya I, Macino G, Pagani M, Cattaneo E, Testa G (2019) Human cortical organoids expose a differential function of GSK3 on cortical neurogenesis. Stem Cell Rep 13(5):847–861. https://doi.org/10.1016/j.stemcr.2019.09.005
doi: 10.1016/j.stemcr.2019.09.005
Duka T, Duka V, Joyce JN, Sidhu A (2009) Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson’s disease models. FASEB J 23(9):2820–2830. https://doi.org/10.1096/fj.08-120410
doi: 10.1096/fj.08-120410 pubmed: 19369384 pmcid: 2796901
Loomes R, Hull L, Mandy WPL (2017) What is the male-to-female ratio in autism spectrum disorder? A systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry 56(6):466–474. https://doi.org/10.1016/j.jaac.2017.03.013
doi: 10.1016/j.jaac.2017.03.013 pubmed: 28545751
Mukherjee SB (2017) Autism spectrum disorders—diagnosis and management. Indian J Pediatr 84(4):307–314. https://doi.org/10.1007/s12098-016-2272-2
doi: 10.1007/s12098-016-2272-2 pubmed: 28101829
Hodges H, Fealko C, Soares N (2020) Autism spectrum disorder: definition, epidemiology, causes, and clinical evaluation. Transl Pediatr 9(Suppl 1):S55–S65. https://doi.org/10.21037/tp.2019.09.09
doi: 10.21037/tp.2019.09.09 pubmed: 32206584 pmcid: 7082249
Fett-Conte AC, Bossolani-Martins AL, Rosan DBA (2015) Etiology of autism the complexity of risk factors in autism spectrum disorder. In: Autism spectrum disorder—recent advances. IntechOpen. https://doi.org/10.5772/59109
Yoo H (2015) Genetics of autism spectrum disorder: current status and possible clinical applications. Exp Neurobiol 24(4):257–272. https://doi.org/10.5607/en.2015.24.4.257
doi: 10.5607/en.2015.24.4.257 pubmed: 26713075 pmcid: 4688327
Schaaf CP, Zoghbi HY (2011) Solving the autism puzzle a few pieces at a time. Neuron 70(5):806–808. https://doi.org/10.1016/j.neuron.2011.05.025
doi: 10.1016/j.neuron.2011.05.025 pubmed: 21658575
Varela-Nallar L, Inestrosa NC (2013) Wnt signaling in the regulation of adult hippocampal neurogenesis. Front Cell Neurosci 7:100. https://doi.org/10.3389/fncel.2013.00100
doi: 10.3389/fncel.2013.00100 pubmed: 23805076 pmcid: 3693081
Kumar S, Reynolds K, Ji Y, Gu R, Rai S, Zhou CJ (2019) Impaired neurodevelopmental pathways in autism spectrum disorder: a review of signaling mechanisms and crosstalk. J Neurodev Disord 11(1):10. https://doi.org/10.1186/s11689-019-9268-y
doi: 10.1186/s11689-019-9268-y pubmed: 31202261 pmcid: 6571119
Moon RT, Kohn AD, De Ferrari GV, Kaykas A (2004) WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5(9):691–701. https://doi.org/10.1038/nrg1427
doi: 10.1038/nrg1427 pubmed: 15372092
Caracci MO, Avila ME, De Ferrari GV (2016) Synaptic Wnt/GSK3beta signaling hub in Autism. Neural Plast 2016:9603751. https://doi.org/10.1155/2016/9603751
doi: 10.1155/2016/9603751 pubmed: 26881141 pmcid: 4736967
Dong F, Jiang J, McSweeney C, Zou D, Liu L, Mao Y (2016) Deletion of CTNNB1 in inhibitory circuitry contributes to autism-associated behavioral defects. Hum Mol Genet 25(13):2738–2751. https://doi.org/10.1093/hmg/ddw131
doi: 10.1093/hmg/ddw131 pubmed: 27131348 pmcid: 5181638
Platt RJ, Zhou Y, Slaymaker IM, Shetty AS, Weisbach NR, Kim JA, Sharma J, Desai M, Sood S, Kempton HR, Crabtree GR, Feng G, Zhang F (2017) Chd8 mutation leads to autistic-like behaviors and impaired striatal circuits. Cell Rep 19(2):335–350. https://doi.org/10.1016/j.celrep.2017.03.052
doi: 10.1016/j.celrep.2017.03.052 pubmed: 28402856 pmcid: 5455342
Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ, Ercan-Sencicek AG, DiLullo NM, Parikshak NN, Stein JL, Walker MF, Ober GT, Teran NA, Song Y, El-Fishawy P, Murtha RC, Choi M, Overton JD, Bjornson RD, Carriero NJ, Meyer KA, Bilguvar K, Mane SM, Sestan N, Lifton RP, Günel M, Roeder K, Geschwind DH, Devlin B, State MW (2012) De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature 485(7397):237–241. https://doi.org/10.1038/nature10945
doi: 10.1038/nature10945 pubmed: 22495306 pmcid: 3667984
Kalkman HO (2012) A review of the evidence for the canonical Wnt pathway in autism spectrum disorders. Mol Autism 3(1):10. https://doi.org/10.1186/2040-2392-3-10
doi: 10.1186/2040-2392-3-10 pubmed: 23083465 pmcid: 3492093
Bernier R, Golzio C, Xiong B, Stessman HA, Coe BP, Penn O, Witherspoon K, Gerdts J, Baker C, Vulto-van Silfhout AT, Schuurs-Hoeijmakers JH, Fichera M, Bosco P, Buono S, Alberti A, Failla P, Peeters H, Steyaert J, Vissers L, Francescatto L, Mefford HC, Rosenfeld JA, Bakken T, O’Roak BJ, Pawlus M, Moon R, Shendure J, Amaral DG, Lein E, Rankin J, Romano C, de Vries BBA, Katsanis N, Eichler EE (2014) Disruptive CHD8 mutations define a subtype of autism early in development. Cell 158(2):263–276. https://doi.org/10.1016/j.cell.2014.06.017
doi: 10.1016/j.cell.2014.06.017 pubmed: 24998929 pmcid: 4136921
Borrie SC, Brems H, Legius E, Bagni C (2017) Cognitive dysfunctions in intellectual disabilities: the contributions of the Ras-MAPK and PI3K-AKT-mTOR pathways. Annu Rev Genomics Hum Genet 18:115–142. https://doi.org/10.1146/annurev-genom-091416-035332
doi: 10.1146/annurev-genom-091416-035332 pubmed: 28859574
Li X, Wu C, Chen N, Gu H, Yen A, Cao L, Wang E, Wang L (2016) PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget 7(22):33440–33450. https://doi.org/10.18632/oncotarget.7961
doi: 10.18632/oncotarget.7961 pubmed: 26967052 pmcid: 5078108
Zhang X, He X, Li Q, Kong X, Ou Z, Zhang L, Gong Z, Long D, Li J, Zhang M, Ji W, Zhang W, Xu L, Xuan A (2017) PI3K/AKT/mTOR signaling mediates valproic acid-induced neuronal differentiation of neural stem cells through epigenetic modifications. Stem Cell Rep 8(5):1256–1269. https://doi.org/10.1016/j.stemcr.2017.04.006
doi: 10.1016/j.stemcr.2017.04.006
Winden KD, Ebrahimi-Fakhari D, Sahin M (2018) Abnormal mTOR activation in autism. Annu Rev Neurosci 41:1–23. https://doi.org/10.1146/annurev-neuro-080317-061747
doi: 10.1146/annurev-neuro-080317-061747 pubmed: 29490194
Butler MG, Dasouki MJ, Zhou XP, Talebizadeh Z, Brown M, Takahashi TN, Miles JH, Wang CH, Stratton R, Pilarski R, Eng C (2005) Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet 42(4):318–321. https://doi.org/10.1136/jmg.2004.024646
doi: 10.1136/jmg.2004.024646 pubmed: 15805158 pmcid: 1736032
Caban C, Khan N, Hasbani DM, Crino PB (2017) Genetics of tuberous sclerosis complex: implications for clinical practice. Appl Clin Genet 10:1–8. https://doi.org/10.2147/TACG.S90262
doi: 10.2147/TACG.S90262 pubmed: 28053551
Lugo JN, Smith GD, Arbuckle EP, White J, Holley AJ, Floruta CM, Ahmed N, Gomez MC, Okonkwo O (2014) Deletion of PTEN produces autism-like behavioral deficits and alterations in synaptic proteins. Front Mol Neurosci 7:27. https://doi.org/10.3389/fnmol.2014.00027
doi: 10.3389/fnmol.2014.00027 pubmed: 24795561 pmcid: 3997048
Kwon CH, Luikart BW, Powell CM, Zhou J, Matheny SA, Zhang W, Li Y, Baker SJ, Parada LF (2006) Pten regulates neuronal arborization and social interaction in mice. Neuron 50(3):377–388. https://doi.org/10.1016/j.neuron.2006.03.023
doi: 10.1016/j.neuron.2006.03.023 pubmed: 16675393 pmcid: 3902853
Schroeder JC, Reim D, Boeckers TM, Schmeisser MJ (2017) Genetic animal models for autism spectrum disorder. Curr Top Behav Neurosci 30:311–324. https://doi.org/10.1007/7854_2015_407
doi: 10.1007/7854_2015_407 pubmed: 26602248
Qin L, Dai X, Yin Y (2016) Valproic acid exposure sequentially activates Wnt and mTOR pathways in rats. Mol Cell Neurosci 75:27–35. https://doi.org/10.1016/j.mcn.2016.06.004
doi: 10.1016/j.mcn.2016.06.004 pubmed: 27343825
Kotajima-Murakami H, Kobayashi T, Kashii H, Sato A, Hagino Y, Tanaka M, Nishito Y, Takamatsu Y, Uchino S, Ikeda K (2019) Effects of rapamycin on social interaction deficits and gene expression in mice exposed to valproic acid in utero. Mol Brain 12(1):3. https://doi.org/10.1186/s13041-018-0423-2
doi: 10.1186/s13041-018-0423-2 pubmed: 30621732 pmcid: 6325753
Halepoto DM, Bashir S, Zeina R, Al-Ayadhi LY (2015) Correlation between Hedgehog (Hh) protein family and brain-derived neurotrophic factor (BDNF) in autism spectrum disorder (ASD). J Coll Phys Surg Pak 25(12):882–885
Lai X, Wu X, Hou N, Liu S, Li Q, Yang T, Miao J, Dong Z, Chen J, Li T (2018) Vitamin A deficiency induces autistic-like behaviors in rats by regulating the RARβ-CD38-oxytocin axis in the hypothalamus. Mol Nutr Food Res. https://doi.org/10.1002/mnfr.201700754
doi: 10.1002/mnfr.201700754 pubmed: 29266770
Wen Y, Alshikho MJ, Herbert MR (2016) Pathway network analyses for autism reveal multisystem involvement, major overlaps with other diseases and convergence upon MAPK and calcium signaling. PLoS ONE 11(4):e0153329. https://doi.org/10.1371/journal.pone.0153329
doi: 10.1371/journal.pone.0153329 pubmed: 27055244 pmcid: 4824422
Pandey MK, DeGrado TR (2016) Glycogen synthase kinase-3 (GSK-3)-targeted therapy and imaging. Theranostics 6(4):571–593. https://doi.org/10.7150/thno.14334
doi: 10.7150/thno.14334 pubmed: 26941849 pmcid: 4775866
Cohen P (1979) The hormonal control of glycogen metabolism in mammalian muscle by multivalent phosphorylation. Biochem Soc Trans 7(3):459–480. https://doi.org/10.1042/bst0070459
doi: 10.1042/bst0070459 pubmed: 221283
Embi N, Rylatt DB, Cohen P (1980) Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 107(2):519–527
doi: 10.1111/j.1432-1033.1980.tb06059.x
Summers SA, Kao AW, Kohn AD, Backus GS, Roth RA, Pessin JE, Birnbaum MJ (1999) The role of glycogen synthase kinase 3beta in insulin-stimulated glucose metabolism. J Biol Chem 274(25):17934–17940. https://doi.org/10.1074/jbc.274.25.17934
doi: 10.1074/jbc.274.25.17934 pubmed: 10364240
Montori-Grau M, Tarrats N, Osorio-Conles O, Orozco A, Serrano-Marco L, Vazquez-Carrera M, Gomez-Foix AM (2013) Glucose dependence of glycogen synthase activity regulation by GSK3 and MEK/ERK inhibitors and angiotensin-(1–7) action on these pathways in cultured human myotubes. Cell Signal 25(5):1318–1327. https://doi.org/10.1016/j.cellsig.2013.02.014
doi: 10.1016/j.cellsig.2013.02.014 pubmed: 23453973
Grimes CA, Jope RS (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65(4):391–426. https://doi.org/10.1016/s0301-0082(01)00011-9
doi: 10.1016/s0301-0082(01)00011-9 pubmed: 11527574
Tullai JW, Chen J, Schaffer ME, Kamenetsky E, Kasif S, Cooper GM (2007) Glycogen synthase kinase-3 represses cyclic AMP response element-binding protein (CREB)-targeted immediate early genes in quiescent cells. J Biol Chem 282(13):9482–9491. https://doi.org/10.1074/jbc.M700067200
doi: 10.1074/jbc.M700067200 pubmed: 17277356 pmcid: 1839957
Morfini G, Szebenyi G, Elluru R, Ratner N, Brady ST (2002) Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J 21(3):281–293. https://doi.org/10.1093/emboj/21.3.281
doi: 10.1093/emboj/21.3.281 pubmed: 11823421 pmcid: 125832
Cui H, Meng Y, Bulleit RF (1998) Inhibition of glycogen synthase kinase 3beta activity regulates proliferation of cultured cerebellar granule cells. Brain Res Dev Brain Res 111(2):177–188. https://doi.org/10.1016/s0165-3806(98)00136-9
doi: 10.1016/s0165-3806(98)00136-9 pubmed: 9838099
Taylor A, Rudd CE (2020) Glycogen synthase kinase 3 (GSK-3) controls T-cell motility and interactions with antigen presenting cells. BMC Res Notes 13(1):163. https://doi.org/10.1186/s13104-020-04971-0
doi: 10.1186/s13104-020-04971-0 pubmed: 32188506 pmcid: 7079518
Jacobs KM, Bhave SR, Ferraro DJ, Jaboin JJ, Hallahan DE, Thotala D (2012) GSK-3beta: a bifunctional role in cell death pathways. Int J Cell Biol 2012:930710. https://doi.org/10.1155/2012/930710
doi: 10.1155/2012/930710 pubmed: 22675363 pmcid: 3364548
Watcharasit P, Bijur GN, Zmijewski JW, Song L, Zmijewska A, Chen X, Johnson GVW, Jope RS (2002) Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage. Proc Natl Acad Sci USA 99(12):7951–7955. https://doi.org/10.1073/pnas.122062299
doi: 10.1073/pnas.122062299 pubmed: 12048243
Cole A (2012) GSK3 as a Sensor Determining Cell Fate in the Brain. Front Mol Neurosci 5:4
pubmed: 22363258 pmcid: 3275790
Ferrer I, Barrachina M, Puig B (2002) Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer’s disease, Pick’s disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol 104(6):583–591. https://doi.org/10.1007/s00401-002-0587-8
doi: 10.1007/s00401-002-0587-8 pubmed: 12410379
Woodgett JR (1990) Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 9(8):2431–2438
doi: 10.1002/j.1460-2075.1990.tb07419.x
Cortes-Vieyra R, Silva-Garcia O, Oviedo-Boyso J, Huante-Mendoza A, Bravo-Patino A, Valdez-Alarcon JJ, Finlay BB, Baizabal-Aguirre VM (2015) The glycogen synthase kinase 3alpha and beta Isoforms differentially regulates interleukin-12p40 expression in endothelial cells stimulated with peptidoglycan from Staphylococcus aureus. PLoS ONE 10(7):e0132867. https://doi.org/10.1371/journal.pone.0132867
doi: 10.1371/journal.pone.0132867 pubmed: 26200352 pmcid: 4511647
Liang MH, Chuang DM (2006) Differential roles of glycogen synthase kinase-3 isoforms in the regulation of transcriptional activation. J Biol Chem 281(41):30479–30484. https://doi.org/10.1074/jbc.M607468200
doi: 10.1074/jbc.M607468200 pubmed: 16912034
Kaidanovich-Beilin O, Woodgett JR (2011) GSK-3: functional insights from cell biology and animal models. Front Mol Neurosci 4:40. https://doi.org/10.3389/fnmol.2011.00040
doi: 10.3389/fnmol.2011.00040 pubmed: 22110425 pmcid: 3217193
Kaidanovich-Beilin O, Beaulieu J-M, Jope RS, Woodgett JR (2012) Neurological functions of the masterswitch protein kinase - gsk-3. Front Mol Neurosci 5:48–48. https://doi.org/10.3389/fnmol.2012.00048
doi: 10.3389/fnmol.2012.00048 pubmed: 22509152 pmcid: 3321477
Pandey GN, Dwivedi Y, Rizavi HS, Teppen T, Gaszner GL, Roberts RC, Conley RR (2009) GSK-3beta gene expression in human postmortem brain: regional distribution, effects of age and suicide. Neurochem Res 34(2):274–285. https://doi.org/10.1007/s11064-008-9770-1
doi: 10.1007/s11064-008-9770-1 pubmed: 18584322
Forde JE, Dale TC (2007) Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life Sci 64(15):1930–1944. https://doi.org/10.1007/s00018-007-7045-7
doi: 10.1007/s00018-007-7045-7 pubmed: 17530463
Mukai F, Ishiguro K, Sano Y, Fujita SC (2002) Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3beta. J Neurochem 81(5):1073–1083. https://doi.org/10.1046/j.1471-4159.2002.00918.x
doi: 10.1046/j.1471-4159.2002.00918.x pubmed: 12065620
Soutar MP, Kim WY, Williamson R, Peggie M, Hastie CJ, McLauchlan H, Snider WD, Gordon-Weeks PR, Sutherland C (2010) Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain. J Neurochem 115(4):974–983. https://doi.org/10.1111/j.1471-4159.2010.06988.x
doi: 10.1111/j.1471-4159.2010.06988.x pubmed: 20831597
Saeki K, Machida M, Kinoshita Y, Takasawa R, Tanuma S (2011) Glycogen synthase kinase-3β2 has lower phosphorylation activity to tau than glycogen synthase kinase-3β1. Biol Pharm Bull 34(1):146–149. https://doi.org/10.1248/bpb.34.146
doi: 10.1248/bpb.34.146 pubmed: 21212533
Zhang F, Phiel CJ, Spece L, Gurvich N, Klein PS (2003) Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem 278(35):33067–33077. https://doi.org/10.1074/jbc.M212635200
doi: 10.1074/jbc.M212635200 pubmed: 12796505
Jope RS, Johnson GV (2004) The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29(2):95–102. https://doi.org/10.1016/j.tibs.2003.12.004
doi: 10.1016/j.tibs.2003.12.004 pubmed: 15102436
Sayas CL, Ariaens A, Ponsioen B, Moolenaar WH (2006) GSK-3 is activated by the tyrosine kinase Pyk2 during LPA1-mediated neurite retraction. Mol Biol Cell 17(4):1834–1844. https://doi.org/10.1091/mbc.e05-07-0688
doi: 10.1091/mbc.e05-07-0688 pubmed: 16452634 pmcid: 1415316
Hughes K, Nikolakaki E, Plyte SE, Totty NF, Woodgett JR (1993) Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J 12(2):803–808
doi: 10.1002/j.1460-2075.1993.tb05715.x
Cole A, Frame S, Cohen P (2004) Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochem J 377(Pt 1):249–255. https://doi.org/10.1042/BJ20031259
doi: 10.1042/BJ20031259 pubmed: 14570592 pmcid: 1223856
Bijur GN, Jope RS (2003) Glycogen synthase kinase-3 beta is highly activated in nuclei and mitochondria. NeuroReport 14(18):2415–2419. https://doi.org/10.1097/00001756-200312190-00025
doi: 10.1097/00001756-200312190-00025 pubmed: 14663202
Azoulay-Alfaguter I, Yaffe Y, Licht-Murava A, Urbanska M, Jaworski J, Pietrokovski S, Hirschberg K, Eldar-Finkelman H (2011) Distinct molecular regulation of glycogen synthase kinase-3alpha isozyme controlled by its N-terminal region: functional role in calcium/calpain signaling. J Biol Chem 286(15):13470–13480. https://doi.org/10.1074/jbc.M110.127969
doi: 10.1074/jbc.M110.127969 pubmed: 21266584 pmcid: 3075693
Hoshi M, Sato M, Kondo S, Takashima A, Noguchi K, Takahashi M, Ishiguro K, Imahori K (1995) Different localization of tau protein kinase I/glycogen synthase kinase-3 beta from glycogen synthase kinase-3 alpha in cerebellum mitochondria. J Biochem 118(4):683–685. https://doi.org/10.1093/oxfordjournals.jbchem.a124965
doi: 10.1093/oxfordjournals.jbchem.a124965 pubmed: 8576078
Bijur GN, Jope RS (2001) Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 beta. J Biol Chem 276(40):37436–37442. https://doi.org/10.1074/jbc.M105725200
doi: 10.1074/jbc.M105725200 pubmed: 11495916 pmcid: 1973163
Yang K, Chen Z, Gao J, Shi W, Li L, Jiang S, Hu H, Liu Z, Xu D, Wu L (2017) The key roles of GSK-3β in regulating mitochondrial activity. Cell Physiol Biochem 44(4):1445–1459. https://doi.org/10.1159/000485580
doi: 10.1159/000485580 pubmed: 29190615
Garrido JJ, Simon D, Varea O, Wandosell F (2007) GSK3 alpha and GSK3 beta are necessary for axon formation. FEBS Lett 581(8):1579–1586. https://doi.org/10.1016/j.febslet.2007.03.018
doi: 10.1016/j.febslet.2007.03.018 pubmed: 17391670
Medina M, Wandosell F (2011) Deconstructing GSK-3: The Fine Regulation of Its Activity. Int J Alzheimer’s Dis 2011:479249. https://doi.org/10.4061/2011/479249
doi: 10.4061/2011/479249
Dajani R, Fraser E, Roe SM, Young N, Good V, Dale TC, Pearl LH (2001) Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 105(6):721–732. https://doi.org/10.1016/s0092-8674(01)00374-9
doi: 10.1016/s0092-8674(01)00374-9 pubmed: 11440715
Frame S, Cohen P, Biondi RM (2001) A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell 7(6):1321–1327. https://doi.org/10.1016/s1097-2765(01)00253-2
doi: 10.1016/s1097-2765(01)00253-2 pubmed: 11430833
Fiol CJ, Mahrenholz AM, Wang Y, Roeske RW, Roach PJ (1987) Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3. J Biol Chem 262 (29):14042–14048
Wang Y, Roach PJ (1993) Inactivation of rabbit muscle glycogen synthase by glycogen synthase kinase-3. Dominant role of the phosphorylation of Ser-640 (site-3a). J Biol Chem 268 (32):23876–23880
Sengupta A, Wu Q, Grundke-Iqbal I, Iqbal K, Singh TJ (1997) Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5. Mol Cell Biochem 167(1–2):99–105. https://doi.org/10.1023/a:1006883924775
doi: 10.1023/a:1006883924775 pubmed: 9059986
Nishimura I, Yang Y, Lu B (2004) PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell 116(5):671–682. https://doi.org/10.1016/s0092-8674(04)00170-9
doi: 10.1016/s0092-8674(04)00170-9 pubmed: 15006350
Amit S, Hatzubai A, Birman Y, Andersen JS, Ben-Shushan E, Mann M, Ben-Neriah Y, Alkalay I (2002) Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev 16(9):1066–1076. https://doi.org/10.1101/gad.230302
doi: 10.1101/gad.230302 pubmed: 12000790 pmcid: 186245
Jia J, Amanai K, Wang G, Tang J, Wang B, Jiang J (2002) Shaggy/GSK3 antagonizes Hedgehog signalling by regulating Cubitus interruptus. Nature 416(6880):548–552. https://doi.org/10.1038/nature733
doi: 10.1038/nature733 pubmed: 11912487
Twomey C, McCarthy JV (2006) Presenilin-1 is an unprimed glycogen synthase kinase-3beta substrate. FEBS Lett 580(17):4015–4020. https://doi.org/10.1016/j.febslet.2006.06.035
doi: 10.1016/j.febslet.2006.06.035 pubmed: 16814287
Goni-Oliver P, Lucas JJ, Avila J, Hernandez F (2007) N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. J Biol Chem 282(31):22406–22413. https://doi.org/10.1074/jbc.M702793200
doi: 10.1074/jbc.M702793200 pubmed: 17569662
Kandasamy AD, Schulz R (2009) Glycogen synthase kinase-3beta is activated by matrix metalloproteinase-2 mediated proteolysis in cardiomyoblasts. Cardiovasc Res 83(4):698–706. https://doi.org/10.1093/cvr/cvp175
doi: 10.1093/cvr/cvp175 pubmed: 19493954
Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378(6559):785–789. https://doi.org/10.1038/378785a0
doi: 10.1038/378785a0 pubmed: 8524413
Ding VW, Chen RH, McCormick F (2000) Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling. J Biol Chem 275(42):32475–32481. https://doi.org/10.1074/jbc.M005342200
doi: 10.1074/jbc.M005342200 pubmed: 10913153
Al-Khouri AM, Ma Y, Togo SH, Williams S, Mustelin T (2005) Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J Biol Chem 280(42):35195–35202. https://doi.org/10.1074/jbc.M503045200
doi: 10.1074/jbc.M503045200 pubmed: 16107342
Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, Wang CY, He X, MacDougald OA, You M, Williams BO, Guan KL (2006) TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126(5):955–968. https://doi.org/10.1016/j.cell.2006.06.055
doi: 10.1016/j.cell.2006.06.055 pubmed: 16959574
Mak BC, Kenerson HL, Aicher LD, Barnes EA, Yeung RS (2005) Aberrant beta-catenin signaling in tuberous sclerosis. Am J Pathol 167(1):107–116. https://doi.org/10.1016/s0002-9440(10)62958-6
doi: 10.1016/s0002-9440(10)62958-6 pubmed: 15972957 pmcid: 1603434
Koo J, Wu X, Mao Z, Khuri FR, Sun SY (2015) Rictor undergoes glycogen synthase kinase 3 (GSK3)-dependent, FBXW7-mediated ubiquitination and proteasomal degradation. J Biol Chem 290(22):14120–14129. https://doi.org/10.1074/jbc.M114.633057
doi: 10.1074/jbc.M114.633057 pubmed: 25897075 pmcid: 4447982
Gulen MF, Bulek K, Xiao H, Yu M, Gao J, Sun L, Beurel E, Kaidanovich-Beilin O, Fox PL, DiCorleto PE, Wang JA, Qin J, Wald DN, Woodgett JR, Jope RS, Carman J, Dongre A, Li X (2012) Inactivation of the enzyme GSK3α by the kinase IKKi promotes AKT-mTOR signaling pathway that mediates interleukin-1-induced Th17 cell maintenance. Immunity 37(5):800–812. https://doi.org/10.1016/j.immuni.2012.08.019
doi: 10.1016/j.immuni.2012.08.019 pubmed: 23142783 pmcid: 3512562
Lathia JD, Mattson MP, Cheng A (2008) Notch: from neural development to neurological disorders. J Neurochem 107(6):1471–1481. https://doi.org/10.1111/j.1471-4159.2008.05715.x
doi: 10.1111/j.1471-4159.2008.05715.x pubmed: 19094054 pmcid: 4544712
Foltz DR, Santiago MC, Berechid BE, Nye JS (2002) Glycogen synthase kinase-3beta modulates notch signaling and stability. Curr Biol 12(12):1006–1011. https://doi.org/10.1016/s0960-9822(02)00888-6
doi: 10.1016/s0960-9822(02)00888-6 pubmed: 12123574
Espinosa L, Ingles-Esteve J, Aguilera C, Bigas A (2003) Phosphorylation by glycogen synthase kinase-3 beta down-regulates Notch activity, a link for Notch and Wnt pathways. J Biol Chem 278(34):32227–32235. https://doi.org/10.1074/jbc.M304001200
doi: 10.1074/jbc.M304001200 pubmed: 12794074
Choudhry Z, Rikani AA, Choudhry AM, Tariq S, Zakaria F, Asghar MW, Sarfraz MK, Haider K, Shafiq AA, Mobassarah NJ (2014) Sonic hedgehog signalling pathway: a complex network. Ann Neurosci 21(1):28–31. https://doi.org/10.5214/ans.0972.7531.210109
doi: 10.5214/ans.0972.7531.210109 pubmed: 25206052 pmcid: 4117150
Jiang J, Hui CC (2008) Hedgehog signaling in development and cancer. Dev Cell 15(6):801–812. https://doi.org/10.1016/j.devcel.2008.11.010
doi: 10.1016/j.devcel.2008.11.010 pubmed: 19081070 pmcid: 6443374
Chen Y, Yue S, Xie L, Pu XH, Jin T, Cheng SY (2011) Dual Phosphorylation of suppressor of fused (Sufu) by PKA and GSK3beta regulates its stability and localization in the primary cilium. J Biol Chem 286(15):13502–13511. https://doi.org/10.1074/jbc.M110.217604
doi: 10.1074/jbc.M110.217604 pubmed: 21317289 pmcid: 3075696
Chen G, Bower KA, Xu M, Ding M, Shi X, Ke ZJ, Luo J (2009) Cyanidin-3-glucoside reverses ethanol-induced inhibition of neurite outgrowth: role of glycogen synthase kinase 3 Beta. Neurotoxicol Res 15(4):321–331. https://doi.org/10.1007/s12640-009-9036-y
doi: 10.1007/s12640-009-9036-y
Gao L, Zhao M, Ye W, Huang J, Chu J, Yan S, Wang C, Zeng R (2016) Inhibition of glycogen synthase kinase-3 (GSK3) promotes the neural differentiation of full-term amniotic fluid-derived stem cells towards neural progenitor cells. Tissue Cell 48(4):312–320. https://doi.org/10.1016/j.tice.2016.06.001
doi: 10.1016/j.tice.2016.06.001 pubmed: 27346451
Barnes AP, Lilley BN, Pan YA, Plummer LJ, Powell AW, Raines AN, Sanes JR, Polleux F (2007) LKB1 and SAD kinases define a pathway required for the polarization of cortical neurons. Cell 129(3):549–563. https://doi.org/10.1016/j.cell.2007.03.025
doi: 10.1016/j.cell.2007.03.025 pubmed: 17482548
Gärtner A, Huang X, Hall A (2006) Neuronal polarity is regulated by glycogen synthase kinase-3 (GSK-3β) independently of Akt/PKB serine phosphorylation. J Cell Sci 119(19):3927. https://doi.org/10.1242/jcs.03159
doi: 10.1242/jcs.03159 pubmed: 16954147
Jiang H, Guo W, Liang X, Rao Y (2005) Both the establishment and the maintenance of neuronal polarity require active mechanisms: critical roles of GSK-3beta and its upstream regulators. Cell 120(1):123–135. https://doi.org/10.1016/j.cell.2004.12.033
doi: 10.1016/j.cell.2004.12.033 pubmed: 15652487
Rahimi-Balaei M, Bergen H, Kong J, Marzban H (2018) Neuronal migration during development of the cerebellum. Front Cell Neurosci 12:484. https://doi.org/10.3389/fncel.2018.00484
doi: 10.3389/fncel.2018.00484 pubmed: 30618631 pmcid: 6304365
Morgan-Smith M, Wu Y, Zhu X, Pringle J, Snider WD (2014) GSK-3 signaling in developing cortical neurons is essential for radial migration and dendritic orientation. Elife 3:e02663. https://doi.org/10.7554/eLife.02663
doi: 10.7554/eLife.02663 pubmed: 25073924 pmcid: 4109311
Asada N, Sanada K (2010) LKB1-mediated spatial control of GSK3beta and adenomatous polyposis coli contributes to centrosomal forward movement and neuronal migration in the developing neocortex. J Neurosci 30(26):8852–8865. https://doi.org/10.1523/JNEUROSCI.6140-09.2010
doi: 10.1523/JNEUROSCI.6140-09.2010 pubmed: 20592207 pmcid: 6632896
Yang X, Klein R, Tian X, Cheng HT, Kopan R, Shen J (2004) Notch activation induces apoptosis in neural progenitor cells through a p53-dependent pathway. Dev Biol 269(1):81–94. https://doi.org/10.1016/j.ydbio.2004.01.014
doi: 10.1016/j.ydbio.2004.01.014 pubmed: 15081359
Depaepe V, Suarez-Gonzalez N, Dufour A, Passante L, Gorski JA, Jones KR, Ledent C, Vanderhaeghen P (2005) Ephrin signalling controls brain size by regulating apoptosis of neural progenitors. Nature 435(7046):1244–1250. https://doi.org/10.1038/nature03651
doi: 10.1038/nature03651 pubmed: 15902206
Eom T-Y, Roth KA, Jope RS (2007) Neural precursor cells are protected from apoptosis induced by trophic factor withdrawal or genotoxic stress by inhibitors of glycogen synthase kinase 3. J Biol Chem 282(31):22856–22864. https://doi.org/10.1074/jbc.M702973200
doi: 10.1074/jbc.M702973200 pubmed: 17548347 pmcid: 2140256
Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 20(1–2):27–39. https://doi.org/10.1093/emboj/20.1.27
doi: 10.1093/emboj/20.1.27 pubmed: 11226152 pmcid: 140191
Hetman M, Cavanaugh JE, Kimelman D, Xia Z (2000) Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. J Neurosci 20(7):2567–2574. https://doi.org/10.1523/JNEUROSCI.20-07-02567.2000
doi: 10.1523/JNEUROSCI.20-07-02567.2000 pubmed: 10729337 pmcid: 6772233
Kozikowski AP, Gaisina IN, Petukhov PA, Sridhar J, King LT, Blond SY, Duka T, Rusnak M, Sidhu A (2006) Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson’s disease. ChemMedChem 1(2):256–266. https://doi.org/10.1002/cmdc.200500039
doi: 10.1002/cmdc.200500039 pubmed: 16892358
Beaulieu JM, Sotnikova TD, Yao WD, Kockeritz L, Woodgett JR, Gainetdinov RR, Caron MG (2004) Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA 101(14):5099–5104. https://doi.org/10.1073/pnas.0307921101
doi: 10.1073/pnas.0307921101 pubmed: 15044694
Li X, Liu M, Cai Z, Wang G, Li X (2010) Regulation of glycogen synthase kinase-3 during bipolar mania treatment. Bipolar Disord 12(7):741–752. https://doi.org/10.1111/j.1399-5618.2010.00866.x
doi: 10.1111/j.1399-5618.2010.00866.x pubmed: 21040291 pmcid: 3059222
Onore C, Yang H, Van de Water J, Ashwood P (2017) Dynamic Akt/mTOR signaling in children with autism spectrum disorder. Front Pediatr 5:43
Wu HF, Chen PS, Chen YJ, Lee CW, Chen IT, Lin HC (2017) Alleviation of N-methyl-D-aspartate receptor-dependent long-term depression via regulation of the glycogen synthase kinase-3beta pathway in the amygdala of a valproic acid-induced animal model of autism. Mol Neurobiol 54(7):5264–5276. https://doi.org/10.1007/s12035-016-0074-1
doi: 10.1007/s12035-016-0074-1 pubmed: 27578017
Schneider T, Przewlocki R (2005) Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology 30(1):80–89. https://doi.org/10.1038/sj.npp.1300518
doi: 10.1038/sj.npp.1300518 pubmed: 15238991
Go HS, Kim KC, Choi CS, Jeon SJ, Kwon KJ, Han SH, Lee J, Cheong JH, Ryu JH, Kim CH, Ko KH, Shin CY (2012) Prenatal exposure to valproic acid increases the neural progenitor cell pool and induces macrocephaly in rat brain via a mechanism involving the GSK-3beta/beta-catenin pathway. Neuropharmacology 63(6):1028–1041. https://doi.org/10.1016/j.neuropharm.2012.07.028
doi: 10.1016/j.neuropharm.2012.07.028 pubmed: 22841957
Courchesne E, Carper R, Akshoomoff N (2003) Evidence of brain overgrowth in the first year of life in autism. JAMA 290(3):337–344. https://doi.org/10.1001/jama.290.3.337
doi: 10.1001/jama.290.3.337 pubmed: 12865374
Courchesne E, Mouton PR, Calhoun ME, Semendeferi K, Ahrens-Barbeau C, Hallet MJ, Barnes CC, Pierce K (2011) Neuron number and size in prefrontal cortex of children with autism. JAMA 306(18):2001–2010. https://doi.org/10.1001/jama.2011.1638
doi: 10.1001/jama.2011.1638 pubmed: 22068992
Chanda S, Ang CE, Lee QY, Ghebrial M, Haag D, Shibuya Y, Wernig M, Sudhof TC (2019) Direct reprogramming of human neurons identifies MARCKSL1 as a pathogenic mediator of valproic acid-induced teratogenicity. Cell Stem Cell 25(1):103–119. https://doi.org/10.1016/j.stem.2019.04.021
doi: 10.1016/j.stem.2019.04.021 pubmed: 31155484 pmcid: 6609489
Zhang Y, Sun Y, Wang F, Wang Z, Peng Y, Li R (2012) Downregulating the canonical Wnt/beta-catenin signaling pathway attenuates the susceptibility to autism-like phenotypes by decreasing oxidative stress. Neurochem Res 37(7):1409–1419. https://doi.org/10.1007/s11064-012-0724-2
doi: 10.1007/s11064-012-0724-2 pubmed: 22374471
Zhang Y, Yang C, Yuan G, Wang Z, Cui W, Li R (2015) Sulindac attenuates valproic acid-induced oxidative stress levels in primary cultured cortical neurons and ameliorates repetitive/stereotypic-like movement disorders in Wistar rats prenatally exposed to valproic acid. Int J Mol Med 35(1):263–270. https://doi.org/10.3892/ijmm.2014.1996
doi: 10.3892/ijmm.2014.1996 pubmed: 25384498
Gilman SR, Iossifov I, Levy D, Ronemus M, Wigler M, Vitkup D (2011) Rare de novo variants associated with autism implicate a large functional network of genes involved in formation and function of synapses. Neuron 70(5):898–907. https://doi.org/10.1016/j.neuron.2011.05.021
doi: 10.1016/j.neuron.2011.05.021 pubmed: 21658583 pmcid: 3607702
Hutsler JJ, Zhang H (2010) Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders. Brain Res 1309:83–94. https://doi.org/10.1016/j.brainres.2009.09.120
doi: 10.1016/j.brainres.2009.09.120 pubmed: 19896929
Tang G, Gudsnuk K, Kuo SH, Cotrina ML, Rosoklija G, Sosunov A, Sonders MS, Kanter E, Castagna C, Yamamoto A, Yue Z, Arancio O, Peterson BS, Champagne F, Dwork AJ, Goldman J, Sulzer D (2014) Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits. Neuron 83(5):1131–1143. https://doi.org/10.1016/j.neuron.2014.07.040
doi: 10.1016/j.neuron.2014.07.040 pubmed: 25155956 pmcid: 4159743
Boissart C, Poulet A, Georges P, Darville H, Julita E, Delorme R, Bourgeron T, Peschanski M, Benchoua A (2013) Differentiation from human pluripotent stem cells of cortical neurons of the superficial layers amenable to psychiatric disease modeling and high-throughput drug screening. Transl Psychiatry 3:e294. https://doi.org/10.1038/tp.2013.71
doi: 10.1038/tp.2013.71 pubmed: 23962924 pmcid: 3756296
Ochs SM, Dorostkar MM, Aramuni G, Schon C, Filser S, Poschl J, Kremer A, Van Leuven F, Ovsepian SV, Herms J (2015) Loss of neuronal GSK3beta reduces dendritic spine stability and attenuates excitatory synaptic transmission via beta-catenin. Mol Psychiatry 20(4):482–489. https://doi.org/10.1038/mp.2014.55
doi: 10.1038/mp.2014.55 pubmed: 24912492
Boccitto M, Doshi S, Newton IP, Nathke I, Neve R, Dong F, Mao Y, Zhai J, Zhang L, Kalb R (2016) Opposing actions of the synapse-associated protein of 97-kDa molecular weight (SAP97) and Disrupted in Schizophrenia 1 (DISC1) on Wnt/beta-catenin signaling. Neuroscience 326:22–30. https://doi.org/10.1016/j.neuroscience.2016.03.048
doi: 10.1016/j.neuroscience.2016.03.048 pubmed: 27026592 pmcid: 4853273
Martin PM, Stanley RE, Ross AP, Freitas AE, Moyer CE, Brumback AC, Iafrati J, Stapornwongkul KS, Dominguez S, Kivimae S, Mulligan KA, Pirooznia M, McCombie WR, Potash JB, Zandi PP, Purcell SM, Sanders SJ, Zuo Y, Sohal VS, Cheyette BNR (2018) DIXDC1 contributes to psychiatric susceptibility by regulating dendritic spine and glutamatergic synapse density via GSK3 and Wnt/beta-catenin signaling. Mol Psychiatry 23(2):467–475. https://doi.org/10.1038/mp.2016.184
doi: 10.1038/mp.2016.184 pubmed: 27752079
Arons MH, Thynne CJ, Grabrucker AM, Li D, Schoen M, Cheyne JE, Boeckers TM, Montgomery JM, Garner CC (2012) Autism-associated mutations in ProSAP2/Shank3 impair synaptic transmission and neurexin-neuroligin-mediated transsynaptic signaling. J Neurosci 32(43):14966–14978. https://doi.org/10.1523/JNEUROSCI.2215-12.2012
doi: 10.1523/JNEUROSCI.2215-12.2012 pubmed: 23100419 pmcid: 3752148
Durand CM, Betancur C, Boeckers TM, Bockmann J, Chaste P, Fauchereau F, Nygren G, Rastam M, Gillberg IC, Anckarsater H, Sponheim E, Goubran-Botros H, Delorme R, Chabane N, Mouren-Simeoni MC, de Mas P, Bieth E, Roge B, Heron D, Burglen L, Gillberg C, Leboyer M, Bourgeron T (2007) Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet 39(1):25–27. https://doi.org/10.1038/ng1933
doi: 10.1038/ng1933 pubmed: 17173049
Wang M, Liu X, Hou Y, Zhang H, Kang J, Wang F, Zhao Y, Chen J, Liu X, Wang Y, Wu S (2019) Decrease of GSK-3beta activity in the anterior cingulate cortex of Shank3b (-/-) mice contributes to synaptic and social deficiency. Front Cell Neurosci 13:447. https://doi.org/10.3389/fncel.2019.00447
doi: 10.3389/fncel.2019.00447 pubmed: 31749684 pmcid: 6843030
Fatemi SH, Stary JM, Halt AR, Realmuto GR (2001) Dysregulation of Reelin and Bcl-2 proteins in autistic cerebellum. J Autism Dev Disord 31(6):529–535. https://doi.org/10.1023/a:1013234708757
doi: 10.1023/a:1013234708757 pubmed: 11814262
Fatemi SH, Snow AV, Stary JM, Araghi-Niknam M, Reutiman TJ, Lee S, Brooks AI, Pearce DA (2005) Reelin signaling is impaired in autism. Biol Psychiatry 57(7):777–787. https://doi.org/10.1016/j.biopsych.2004.12.018
doi: 10.1016/j.biopsych.2004.12.018 pubmed: 15820235
Fatemi SH, Reutiman TJ, Folsom TD (2009) Chronic psychotropic drug treatment causes differential expression of Reelin signaling system in frontal cortex of rats. Schizophr Res 111(1–3):138–152. https://doi.org/10.1016/j.schres.2009.03.002
doi: 10.1016/j.schres.2009.03.002 pubmed: 19359144
Chugani DC (2004) Serotonin in autism and pediatric epilepsies. Ment Retard Dev Disabil Res Rev 10(2):112–116. https://doi.org/10.1002/mrdd.20021
doi: 10.1002/mrdd.20021 pubmed: 15362166
Thompson SL, Dulawa SC (2019) Dissecting the roles of beta-arrestin2 and GSK-3 signaling in 5-HT1BR-mediated perseverative behavior and prepulse inhibition deficits in mice. PLoS ONE 14(2):e0211239. https://doi.org/10.1371/journal.pone.0211239
doi: 10.1371/journal.pone.0211239 pubmed: 30721232 pmcid: 6363181
Beaulieu JM, Zhang X, Rodriguiz RM, Sotnikova TD, Cools MJ, Wetsel WC, Gainetdinov RR, Caron MG (2008) Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci USA 105(4):1333–1338. https://doi.org/10.1073/pnas.0711496105
doi: 10.1073/pnas.0711496105 pubmed: 18212115
Wu X, Bai Y, Tan T, Li H, Xia S, Chang X, Zhou Z, Zhou W, Li T, Wang YT, Dong Z (2014) Lithium ameliorates autistic-like behaviors induced by neonatal isolation in rats. Front Behav Neurosci 8:Article e234. https://doi.org/10.3389/fnbeh.2014.00234
Hagerman RJ, Berry-Kravis E, Hazlett HC, Bailey DB Jr, Moine H, Kooy RF, Tassone F, Gantois I, Sonenberg N, Mandel JL, Hagerman PJ (2017) Fragile X syndrome. Nat Rev Dis Primers 3:17065. https://doi.org/10.1038/nrdp.2017.65
doi: 10.1038/nrdp.2017.65 pubmed: 28960184
Lozano R, Rosero CA, Hagerman RJ (2014) Fragile X spectrum disorders. Intractable Rare Dis Res 3(4):134–146. https://doi.org/10.5582/irdr.2014.01022
doi: 10.5582/irdr.2014.01022 pubmed: 25606363 pmcid: 4298643
Bhakar AL, Dolen G, Bear MF (2012) The pathophysiology of fragile X (and what it teaches us about synapses). Annu Rev Neurosci 35:417–443. https://doi.org/10.1146/annurev-neuro-060909-153138
doi: 10.1146/annurev-neuro-060909-153138 pubmed: 22483044 pmcid: 4327822
Franklin AV, King MK, Palomo V, Martinez A, McMahon LL, Jope RS (2014) Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice. Biol Psychiatry 75(3):198–206. https://doi.org/10.1016/j.biopsych.2013.08.003
doi: 10.1016/j.biopsych.2013.08.003 pubmed: 24041505
Guo W, Murthy AC, Zhang L, Johnson EB, Schaller EG, Allan AM, Zhao X (2012) Inhibition of GSK3β improves hippocampus-dependent learning and rescues neurogenesis in a mouse model of fragile X syndrome. Hum Mol Genet 21(3):681–691. https://doi.org/10.1093/hmg/ddr501
doi: 10.1093/hmg/ddr501 pubmed: 22048960
Min WW, Yuskaitis CJ, Yan Q, Sikorski C, Chen S, Jope RS, Bauchwitz RP (2009) Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential. Neuropharmacology 56(2):463–472. https://doi.org/10.1016/j.neuropharm.2008.09.017
doi: 10.1016/j.neuropharm.2008.09.017 pubmed: 18952114
Pardo M, Beurel E, Jope RS (2017) Cotinine administration improves impaired cognition in the mouse model of Fragile X syndrome. Eur J Neurosci 45(4):490–498. https://doi.org/10.1111/ejn.13446
doi: 10.1111/ejn.13446 pubmed: 27775852
Yuskaitis CJ, Mines MA, King MK, Sweatt JD, Miller CA, Jope RS (2010) Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochem Pharmacol 79(4):632–646. https://doi.org/10.1016/j.bcp.2009.09.023
doi: 10.1016/j.bcp.2009.09.023 pubmed: 19799873 pmcid: 2810609
Mines MA, Yuskaitis CJ, King MK, Beurel E, Jope RS (2010) GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism. PLoS ONE 5(3):e9706. https://doi.org/10.1371/journal.pone.0009706
doi: 10.1371/journal.pone.0009706 pubmed: 20300527 pmcid: 2838793
Yuskaitis CJ, Beurel E (1802) Jope RS (2010) Evidence of reactive astrocytes but not peripheral immune system activation in a mouse model of Fragile X syndrome. Biochim Biophys Acta 11:1006–1012. https://doi.org/10.1016/j.bbadis.2010.06.015
doi: 10.1016/j.bbadis.2010.06.015
Pardo M, Cheng Y, Velmeshev D, Magistri M, Eldar-Finkelman H, Martinez A, Faghihi MA, Jope RS, Beurel E (2017) Intranasal siRNA administration reveals IGF2 deficiency contributes to impaired cognition in Fragile X syndrome mice. JCI Insight 2(6):e91782. https://doi.org/10.1172/jci.insight.91782
doi: 10.1172/jci.insight.91782 pubmed: 28352664 pmcid: 5358485
Luo Y, Shan G, Guo W, Smrt RD, Johnson EB, Li X, Pfeiffer RL, Szulwach KE, Duan R, Barkho BZ, Li W, Liu C, Jin P, Zhao X (2010) Fragile x mental retardation protein regulates proliferation and differentiation of adult neural stem/progenitor cells. PLoS Genet 6(4):e1000898. https://doi.org/10.1371/journal.pgen.1000898
doi: 10.1371/journal.pgen.1000898 pubmed: 20386739 pmcid: 2851565
Chen T, Lu JS, Song Q, Liu MG, Koga K, Descalzi G, Li YQ, Zhuo M (2014) Pharmacological rescue of cortical synaptic and network potentiation in a mouse model for fragile X syndrome. Neuropsychopharmacology 39(8):1955–1967. https://doi.org/10.1038/npp.2014.44
doi: 10.1038/npp.2014.44 pubmed: 24553731 pmcid: 4059905
Vainio PJ, Tuominen RK (2001) Cotinine binding to nicotinic acetylcholine receptors in bovine chromaffin cell and rat brain membranes. Nicotine Tob Res 3(2):177–182. https://doi.org/10.1080/14622200110043095
doi: 10.1080/14622200110043095 pubmed: 11403732
McCamphill PK, Stoppel LJ, Senter RK, Lewis MC, Heynen AJ, Stoppel DC, Sridhar V, Collins KA, Shi X, Pan JQ, Madison J, Cottrell JR, Huber KM, Scolnick EM, Holson EB, Wagner FF, Bear MF (2020) Selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile X syndrome. Science Translat Med. https://doi.org/10.1126/scitranslmed.aam8572
doi: 10.1126/scitranslmed.aam8572
Trappe R, Laccone F, Cobilanschi J, Meins M, Huppke P, Hanefeld F, Engel W (2001) MECP2 mutations in sporadic cases of Rett syndrome are almost exclusively of paternal origin. Am J Hum Genet 68(5):1093–1101. https://doi.org/10.1086/320109
doi: 10.1086/320109 pubmed: 11309679 pmcid: 1226090
Psoni S, Sofocleous C, Traeger-Synodinos J, Kitsiou-Tzeli S, Kanavakis E, Fryssira-Kanioura H (2010) Phenotypic and genotypic variability in four males with MECP2 gene sequence aberrations including a novel deletion. Pediatr Res 67(5):551–556. https://doi.org/10.1203/PDR.0b013e3181d4ecf7
doi: 10.1203/PDR.0b013e3181d4ecf7 pubmed: 20098342
Hagberg B, Aicardi J, Dias K, Ramos O (1983) A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett’s syndrome: report of 35 cases. Ann Neurol 14(4):471–479. https://doi.org/10.1002/ana.410140412
doi: 10.1002/ana.410140412 pubmed: 6638958
Schanen NC, Dahle EJ, Capozzoli F, Holm VA, Zoghbi HY, Francke U (1997) A new Rett syndrome family consistent with X-linked inheritance expands the X chromosome exclusion map. Am J Hum Genet 61(3):634–641. https://doi.org/10.1086/515525
doi: 10.1086/515525 pubmed: 9326329 pmcid: 1715972
Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY (1999) Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 23(2):185–188. https://doi.org/10.1038/13810
doi: 10.1038/13810 pubmed: 10508514
Jorge-Torres OC, Szczesna K, Roa L, Casal C, Gonzalez-Somermeyer L, Soler M, Velasco CD, Martinez-San Segundo P, Petazzi P, Saez MA, Delgado-Morales R, Fourcade S, Pujol A, Huertas D, Llobet A, Guil S, Esteller M (2018) Inhibition of Gsk3b reduces Nfkb1 signaling and rescues synaptic activity to improve the Rett syndrome phenotype in Mecp2-Knockout Mice. Cell Rep 23(6):1665–1677. https://doi.org/10.1016/j.celrep.2018.04.010
doi: 10.1016/j.celrep.2018.04.010 pubmed: 29742424
Tang X, Drotar J, Li K, Clairmont CD, Brumm AS, Sullins AJ, Wu H, Liu XS, Wang J, Gray NS, Sur M, Jaenisch R (2019) Pharmacological enhancement of KCC2 gene expression exerts therapeutic effects on human Rett syndrome neurons and Mecp2 mutant mice. Sci Translat Med. https://doi.org/10.1126/scitranslmed.aau0164
doi: 10.1126/scitranslmed.aau0164
Hsu W-L, Ma Y-L, Liu Y-C, Tai DJC, Lee EHY (2020) Restoring Wnt6 signaling ameliorates behavioral deficits in MeCP2 T158A mouse model of Rett syndrome. Sci Rep 10(1):1074. https://doi.org/10.1038/s41598-020-57745-w
doi: 10.1038/s41598-020-57745-w pubmed: 31974426 pmcid: 6978308
Eldar-Finkelman H, Martinez A (2011) GSK-3 inhibitors: preclinical and clinical focus on CNS. Front Mol Neurosci 4:32–32. https://doi.org/10.3389/fnmol.2011.00032
doi: 10.3389/fnmol.2011.00032 pubmed: 22065134 pmcid: 3204427
Cade JF (1949) Lithium salts in the treatment of psychotic excitement. Med J Aust 2(10):349–352. https://doi.org/10.1080/j.1440-1614.1999.06241.x
doi: 10.1080/j.1440-1614.1999.06241.x pubmed: 18142718
Klein PS, Melton DA (1996) A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 93(16):8455–8459. https://doi.org/10.1073/pnas.93.16.8455
doi: 10.1073/pnas.93.16.8455 pubmed: 8710892
Ryves WJ, Dajani R, Pearl L, Harwood AJ (2002) Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. Biochem Biophys Res Commun 290(3):967–972. https://doi.org/10.1006/bbrc.2001.6305
doi: 10.1006/bbrc.2001.6305 pubmed: 11798168
Chuang D-M, Wang Z, Chiu C-T (2011) GSK-3 as a target for lithium-induced neuroprotection against excitotoxicity in neuronal cultures and animal models of ischemic stroke. Front Mol Neurosci 4:15
doi: 10.3389/fnmol.2011.00015
Watcharasit P, Bijur GN, Song L, Zhu J, Chen X, Jope RS (2003) Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53. J Biol Chem 278(49):48872–48879. https://doi.org/10.1074/jbc.M305870200
doi: 10.1074/jbc.M305870200 pubmed: 14523002 pmcid: 1361697
Kramer T, Schmidt B, Lo Monte F (2012) Small-molecule inhibitors of GSK-3: structural insights and their application to Alzheimer’s disease models. Int J Alzheimers Dis 2012:381029. https://doi.org/10.1155/2012/381029
doi: 10.1155/2012/381029 pubmed: 22888461 pmcid: 3408674
Hernandez F, Nido JD, Avila J, Villanueva N (2009) GSK3 inhibitors and disease. Mini Rev Med Chem 9(9):1024–1029. https://doi.org/10.2174/138955709788922647
doi: 10.2174/138955709788922647 pubmed: 19689399
ter Haar E, Walters WP, Pazhanisamy S, Taslimi P, Pierce AC, Bemis GW, Salituro FG, Harbeson SL (2004) Kinase chemogenomics: targeting the human kinome for target validation and drug discovery. Mini Rev Med Chem 4(3):235–253. https://doi.org/10.2174/1389557043487367
doi: 10.2174/1389557043487367 pubmed: 15032672
Cross DA, Culbert AA, Chalmers KA, Facci L, Skaper SD, Reith AD (2001) Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J Neurochem 77(1):94–102. https://doi.org/10.1046/j.1471-4159.2001.t01-1-00251.x
doi: 10.1046/j.1471-4159.2001.t01-1-00251.x pubmed: 11279265
Collino M, Thiemermann C, Mastrocola R, Gallicchio M, Benetti E, Miglio G, Castiglia S, Danni O, Murch O, Dianzani C, Aragno M, Fantozzi R (2008) Treatment with the glycogen synthase kinase-3beta inhibitor, TDZD-8, affects transient cerebral ischemia/reperfusion injury in the rat hippocampus. Shock. https://doi.org/10.1097/SHK.0b013e318164e762
doi: 10.1097/SHK.0b013e318164e762 pubmed: 18323734
Mazanetz MP, Fischer PM (2007) Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discovery 6(6):464–479. https://doi.org/10.1038/nrd2111
doi: 10.1038/nrd2111 pubmed: 17541419
Hall AP, Escott KJ, Sanganee H, Hickling KC (2015) Preclinical toxicity of AZD7969: Effects of GSK3β inhibition in adult stem cells. Toxicol Pathol 43(3):384–399. https://doi.org/10.1177/0192623314544468
doi: 10.1177/0192623314544468 pubmed: 25326587
Kunnimalaiyaan S, Schwartz VK, Jackson IA, Clark Gamblin T, Kunnimalaiyaan M (2018) Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro. BMC Cancer 18(1):560–560. https://doi.org/10.1186/s12885-018-4474-7
doi: 10.1186/s12885-018-4474-7 pubmed: 29751783 pmcid: 5948712
Khanfar MA, Hill RA, Kaddoumi A, El Sayed KA (2010) Discovery of novel GSK-3β inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand- and structure-based virtual screening. J Med Chem 53(24):8534–8545. https://doi.org/10.1021/jm100941j
doi: 10.1021/jm100941j pubmed: 21082766

Auteurs

Mahdi Rizk (M)

Neuroscience Research Center, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.

Zahraa Saker (Z)

Neuroscience Research Center, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.

Hayat Harati (H)

Neuroscience Research Center, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.

Youssef Fares (Y)

Neuroscience Research Center, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.
Department of Neurosurgery, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.

Hisham F Bahmad (HF)

Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, 4300 Alton Rd, Miami Beach, FL, 33140, USA.

Sanaa Nabha (S)

Neuroscience Research Center, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon. snabha@ul.edu.lb.
ORCID: 0000-0002-6578-872X

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Troubles mentaux › Troubles du développement neurologique › Troubles généralisés du développement de l'enfant › Trouble du spectre autistique › Deciphering the roles of glycogen synthase...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-Serine-Threonine Kinases › Proline-directed protein kinases › Glycogen Synthase Kinase 3 › Deciphering the roles of glycogen synthase...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Deciphering the roles of glycogen synthase...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Deciphering the roles of glycogen synthase...
questionsmedicales.fr › Cellules › Structures cellulaires › Membrane cellulaire › Structures de la membrane cellulaire › Jonctions intercellulaires › Synapses › Deciphering the roles of glycogen synthase...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système nerveux › Transmission synaptique › Deciphering the roles of glycogen synthase...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Maladie › Syndrome › Deciphering the roles of glycogen synthase...